LETTERS FOR ISSUE ON
|
|
|
- Benjamin Blankenship
- 5 years ago
- Views:
Transcription
1 S FOR ISSUE ON BIOLOGICAL DIVISION NAME OF COMPANY DY. NO. STATUS M/S ZUVENTUS HEALTHCARE LTD 6981 APPROVAL M/S TECHINVENTION LIFE SCIENCES 1208 CLARIFICATION M/S CADILA PHARMACEUTICALS LTD 6484 APPROVAL M/S BIOCON LTD 6350, 6349, 4832 APPROVAL & CLARIFICATION M/S FERRING PHARMACEUTICALS 7638 APPROVAL M/S GSK 931 ACKNOWLEDGE M/S ABBOTT INDIA LTD 6777 APPROVAL M/S INDOVAX 7428 (FTS NO) APPROVAL M/S JOHNSON & JOHNSON APPROVAL M/S G.C. CHEMIE PHARMIE LTD (FTS NO) APPROVAL M/S BIOMED 8054 APPROVAL M/S ELI LILLY AND COMPANY INDIA M/S SANOFI SYNTHELABO INDIA PVT, LTD M/S GENNOVA BIOPHARMACEUTICALS LTD 6183 APPROVAL 4738,4739 APPROVAL (FTS NO) CLARIFICATION GLOBAL CLINICAL TRIAL SR. NO. COMPANY NAME REFERENCE NO. STATUS 1 M/S. NOVARTIS 6163/1591/5578/6162 TL APPROVAL
2 2 M/S. CLINIRX 1165/607 PA/ SITE APPROVAL S 3 M/S. JSS - MINUTES OF MEETING 4 M/S. IPROCESS 32145/2357 PA / TL APPROVAL S 5 M/S. MAYA CLINICALS 6169 TL APPROVAL 6 M/S. KENDLE 4763 PA/TL APPROVAL S LVP DIVISION S. NO. COMPANY NAME FTS NO. /DIARY NO. STATUS 1. M/S. REALCADE LIFESCIENCES PVT. MEHSANA, GUJARAT 6052, 6055, 6053, 6051, 11717, 11718, 11719, 11720, QUERY COSMETICS DIVISION S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. M/S. AVON BEAUTY PRODUCTS INDIA PVT. GURGAON 4606 APPROVAL 2. M/S. LOTUS HERBALS (P) U.P APPROVAL 3. M/S. WIPRO ENTERPRISES PVT. BANGALORE 7592 APPROVAL 4. M/S. PALSON DERMA PVT. KOLKATA 5385 APPROVAL 5. M/S. FACES COSMETICS INDIA PVT. MUMBAI 5978 APPROVAL 6. M/S. SWEETYET DEVELOPMENT DISTRIBUTION INDIA PVT. MUMBAI 6151 APPROVAL FDC DIVISION S.NO. NAME OF COMPANY DIARY NO. DOCUMENT 1. M/S. CENTAUR PHARMACEUTICALS PVT. LTD M/S. ZUVENTUS HEALTHCARE S 3. M/S. SYNOKEM PHARMACEUTICALS MEDICAL DEVICE
3 S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. SYNERGY PHARMA FORMULATIONS INDIA PVT. LTD CLARIFICATION 2. M/S. GENERAL MEDICAL SYSTEMS PVT. LTD CLARIFICATION 3. M/S. EMERGO (INDIA) CONSULTING PVT. LTD M/S. BAXTER (INDIA) PVT. LTD. NIL 5. M/S. MANJU ENTERPRISES PVT. LTD. ALL PORT OFFICES OF CDSCO 6. M/S. BOSTON SCIENTIFIC INDIA PVT. LTD. ALL PORT OFFICES OF CDSCO 7. M/S. ORTHO LIFE SYSTEMS THE STATE DRUGS CONTROLLER, DELHI NIL NIL FTS. NO THE FOREIGN TRADE DEVELOPMENT OFFICER NIL 9. THE COMMISSIONER, GANDHINAGAR (CLAA) THE DEPUTY DRUGS CONTROLLER, AHMEDABAD (CLAA) (M/S. BONETECH MEDISYS PVT. AHMEDABAD) FTS. NO APPROVAL DIAGNOSTICS DIVISION S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. ROCHE DIAGNOSTICS INDIA PVT. LTD APPROVAL (TEST LICENSE) 2. M/S. ROCHE DIAGNOSTICS INDIA PVT. LTD APPROVAL (TEST LICENSE) 3. M/S. ROCHE DIAGNOSTICS INDIA PVT. LTD M/S. BECTON DICKINSON INDIA PVT. LTD M/S. BECKMAN COULTER INDIA PVT. LTD. 6475
4 6. M/S. KHC HEALTHCARE INDIA PVT. LTD. NIL 7. M/S. SD BIOSENSOR HEALTHCARE PVT. LTD. NIL 8. M/S. SIEMENS HEALTHCARE PVT. LTD. NIL 9. M/S. RELIABLE PRO-DETECTS BIOMEDICAL PVT. LTD. NIL 10. M/S. J. MITRA & CO. PVT. LTD. NIL 11. M/S. BHAT BIO-TECH INDIA(P) LTD. NIL NEW DRUG S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. M/S. DR. REDDY S LABS - TL, IPC, QUERY 2. M/S. VIJAYASRI ORGANIC - IPC, QUERY 3. M/S. AJANTA PHARMA - IPC (2), 4. M/S. EMCURE PHARMACEUTICALS - QUERY 5. M/S. CIPLA LTD. - QUERY 6. M/S. CADILA HEALTHCARE LTD. MEETING ON 7. M/S. TORRENT PHARMACEUTICALS LTD. MEETING ON 8. M/S. INTAS PHARMACEUTICALS LTD. MEETING ON 9. M/S. SPECTRUM ONCOLOGY PVT MEETING ON 10. M/S. WOCKHARDT MEETING ON 11. M/S. GLENMARK PHARMACEUTICALS MEETING ON SUBSEQUENT NEW DRUG S. NO. NAME OF THE FIRM REFERENCE NO. FTS NO. TYPE OF
5 1. M/S AJANTA PHARMA LIMITED., 2. M/S NANZ MED SCIENCE PHARMA PVT. 3. M/S DELTECH HEALTHCARE PVT. 4. M/S JOHNSON & JOHNSON 5. M/S MAPS LABORATORIES PRIVATE LIMITED, 6. M/S ASTELLAS PHARMA INDIA PVT DEFICIENCY, IPC NOC (2) DEFICIENCY DEFICIENCY APPROVAL (2) DEFICIENCY, IPC NOC DEFICIENCY
LETTERS FOR ISSUE ON
S FOR ISSUE ON 04.10.2017 MEDICAL DEVICE DIVISION S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. ABBOTT MEDICAL OPTICS PVT. LTD., 14608 QUERY 2. M/S. ABBOTT MEDICAL OPTICS PVT. LTD., 14609 QUERY 3. DR. ULHAS
LETTERS FOR ISSUE ON
S FOR ISSUE ON 25.04.2017 BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. M/S. ALEMBIC PHARMACEUTICALS 2. M/S. ALEMBIC PHARMACEUTICALS 3. M/S. ALEMBIC PHARMACEUTICALS 4. M/S. EMCURE PHARMACEUTICALS
LETTERS FOR ISSUE ON
S FOR ISSUE ON 01.09.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1. M/S TYCHE INDUSTRIES LTD., ANDHRA PRADESH, INDIA IMPORT S. NAME OF APPLICANT DIARY TYPE OF 1. PIRAMAL ENTERPRISES LTD. 25471 APPROVAL
LETTERS FOR ISSUE ON
S FOR ISSUE ON 19.06.2015 BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. M/S. ACCUTEST RESEARCH LABORATORIES (I) PVT., NAVI MUMBAI-400 709 2. M/S. ACCUTEST RESEARCH LABORATORIES (I) PVT.,
LETTERS FOR ISSUE ON
S FOR ISSUE ON 21.06.2016 LVP DIVISION S. NO. COMPANY NAME FTS NO. /DIARY NO. STATUS 01 M/S. GLOBAL PHARMA HEALTHCARE PVT. LTD., THIRUPORUR 27509 APPROVAL BIOLOGICAL DIVISION NAME OF COMPANY DY.NO. STATUS
LETTERS FOR ISSUE ON
S FOR ISSUE ON 27.08.2015 NEW DRUG S. NAME OF APPLICANT DIARY TYPE OF 1. M/S. INTAS PHARMACEUTICALS LIMITED - CT NOC (2) 2. M/S. PFIZER LIMITED - QUERY 3. M/S. MSN LABORATORIES - ADDITIONAL SITE 4. M/S.
LETTERS FOR ISSUE ON
S FOR ISSUE ON 03.09.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1. M/S LUPIN TARAPUR, MAHARASHTRA & WC 2. M/S JPN PHARMA PVT. PALGHAR, MAHARASHTRA WC 3. M/S OPTIMUS DRUGS A.P. WC VACCINE DIVISION S.
LETTERS FOR ISSUE ON
S FOR ISSUE ON 17.07.2015 NEW DRUG S.NO. NAME OF APPLICANT DIARY TYPE OF NO. 1. M/S. CIREX PHARMACEUTICALS LTD - QUERY 2. M/S. LUPIN LIMITED - ADDITIONAL SITES REGISTRATION S.NO. NAME OF APPLICANT DIARY
TODAY LETTER DATED
TODAY LETTER DATED 26.06.2018 GLOBAL CLINICAL TRIAL SR. NO. COMPANY NAME REFERENCE NO. STATUS 1 M/S. RESEARCH ASSOCIATES INDIA PVT.. 18670 PA APPROVAL LETTER LVP DIVISION S. NO. COMPANY NAME FTS NO. /DIARY
LETTERS FOR ISSUE ON
S FOR ISSUE ON 14.12.2015 LVP DIVISION S. COMPANY NAME FTS /DIARY STATUS 01 M/S. AXA PARENTERALS LTD., ROORKEE 60262 APPROVAL 02 M/S. UNIJULES LIFE SCIENCES LTD., NAGPUR 61147 APPROVAL 03 M/S. INNVOL MEDICAL
LETTERS FOR ISSUE ON
S FOR ISSUE ON 04.12.2015 NEW DRUG S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. M/S. VIRCHOW BIOTECH PVT LTD - QUERY 2. M/S. MSN LABORATORIES PVT - CT-NOC & BE NOC LTD (3) 3. M/S. NATCO PHARMA LTD. - BE-NOC
LETTERS FOR ISSUE ON
S FOR ISSUE ON 14.03.2016 IMPORT S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. TABLETS (INDIA) LIMITED 5973 APPROVAL 2. TABLETS (INDIA) LIMITED 5974 APPROVAL 3. CLARIS OTSUKA PRIVATE LIMITED 7373 APPROVAL
LETTERS FOR ISSUE ON
S FOR ISSUE ON 15.10.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1 M/S NATCO PHARMA LIMITED HYDERABAD MEDICAL DEVICE S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. GENETIX BIOTECH ASIA PVT. LTD. 22073 APPROVAL
LETTERS FOR ISSUE ON
S FOR ISSUE ON 29.11.2016 COSMETICS DIVISION S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. M/S. WELLA INDIA PVT. LTD., MUMBAI 29233, 29524 & 28513 APPROVAL 2. M/S. PROCTER & GAMBLE HOME PRODUCTS PVT. LTD.,
LETTERS FOR ISSUE ON
S FOR ISSUE ON 17.05.2016 BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. M/S. ACCUTEST RESEARCH MUMBAI-400709 2. M/S. ACCUTEST RESEARCH MUMBAI-400709 3. M/S. ACCUTEST RESEARCH MUMBAI-400709
LETTERS FOR ISSUE ON
LETTERS FOR ISSUE ON 27.12.2017 LVP DIVISION S. NO. COMPANY NAME FTS NO. /Diary No. STATUS 01 M/s. Akums Drugs & Pharmaceuticals, Haridwar 02 M/s. Unique Pharmaceutical Laboratories,Guj. (License No.4)
LETTERS FOR ISSUE ON
S FOR ISSUE ON 05.10.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE OF DOCUMENT 1. M/S. ARRIGO INTERNATIONAL,INDORE 2 M/S. EUROLIFE HEALTHCARE PVT. LTD. HARIDWAR NEW DRUG S. NAME OF APPLICANT DIARY TYPE
File no./drug Name Name of firm/ Institute Recommendations. New Drugs Division
Recommendations: I approve the minutes of 52 nd SEC (Oncology & hematology) held on 13.04.2017 at CDSCO HQ New Delhi and recommended the following: Agenda 1 12-63/16-DC Ferric Pyrophosphate citrate solution
RESULTS AND DISCUSSION
RESULTS AND DISCUSSION 203 4.1 General Introduction: The researcher has collected both the primary and secondary data. The primary data is collected by direct interaction by using formal questionnaire
Recommendations of thesec (Dermatology & Allergy) made in its 23 rd meeting held on at CDSCO HQ New Delhi: New Drugs Division
Recommetions of thesec (Dermatology & Allergy) made in its 23 rd meeting held on 11.05.2017 at CDSCO HQ New Delhi: File /Drug Name Recommetions New Drugs Division 1 12-28/15-DC (Pt-B) Apremilast 10/20/30
3. Dr.Rajutitus Chacko, Prof. & Head, Dept. of Medical Oncology, CMC, Vellore.
MINUTES OF THE 6 th MEETING OF TECHNICAL COMMITTEE HELD ON 25-07-2013 UNDER CHAIRMANSHIP OF DGHS FOR SUPERVISING CLINICAL TRIALS ON NEW CHEMICAL ENTITIES IN THE LIGHT OF DIRECTIONS OF THE HON BLE SUPREME
Minimumum Price (Rs.) 3.30 Maximum Price (Rs.) 4.57 Average of all considered (Rs.) 3.73 Retail Price (Rs.) 4.33
Computataion of Retail Price based on Jan.-2016 Data under Para 4 of DPCO 2013 Cholecalciferol 800 IU Drops of M/s Raptakos, Brett & Co.Ltd. Number of Companies cosisting of Market Share of 1% & Above
REGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS REGULATORY UPDATES: APPROVAL, (CONTINUED)... 38
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
1 Agio Pharmaceuticals Limited 15/31/2013-EP(Engg) dt:21.11.2013 7,98,217.00 2 Akriti Pharmaceuticals Pvt Ltd 15/31/2013-EP(Engg) dt:21.11.2013 15,10,268.00 3 Akriti Pharmaceuticals Pvt Ltd 15/31/2013-EP(Engg)
New Delhi, the 18 th December, 2017 ORDER
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of National Pharmaceutical Pricing Authority
Education. Current Activities
Nirali Mehta, M.Sc., M.Phil. Founder & Consultant Biostatistician Ahmedabad, Gujarat, India. M +91 9377060504 E nirali.mehta@pharma-stats.in W www.pharma-stats.in Education 1998-2001 Bachelor of Science
10 th SEC- (Reproductive & Urology)meetingheld on at CDSCO (HQ), FDA Bhawan, Kotla road, New Delhi PROGRAMME SCHEDULE
10 th SEC- (Reproductive & Urology)meetingheld on 16-01-2015 at CDSCO (HQ), FDA Bhawan, Kotla road, New Delhi 110 002 PROGRAMME SCHEDULE Recommendation:- The 10 th SEC (Reproductive and Urology) meeting
ORDER. Table. (1) (2) (3) (4) (5) (6) 1. Glimepiride Metformin Tablet
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of National Pharmaceutical Pricing Authority
Subsequent New Drugs Division. M/s.Troikaa. M/s. Olive Healthcare. Biological Division. M/s. Wockhardt Ltd. Global Clinical Trial Division
: The34 th SEC (Endocrinology & Metabolism) meeting held on 25.04.2017 at CDSCO HQ New Delhi and recommended the following: Age Subsequent New Drugs Division 1 12-146/2016-DC (Pt- Zim-Snd) Vitamin D3 (Cholecalciferol)
TOTAL MAT 1,52,81, % Unit PTR (Rs.) MAT (Rs.) SKU wise MAT % प क व रण Pack Description छ प BRAND. क पन Company. S. No. Unique No.
Number of Companies consisting of Market Share of 1% & Above 2 3.1 Adrenaline Injection 1 mg/ml Per ml Sum of MAT value considered for price calculation (in Lakhs) 152.69 Sum of PTR per unit considered
BRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
Status of Import License (Form 10) of Recombinant Products, Human and Veterinary Vaccines issued from 01/03/2016 to 29/04/2016
1. M/s LG Life Sciences India Pvt. Ltd.,Basement Commercial SCO No. 321, Sector-29, Gurgaon, India 2. M/s Eli Lilly and Co (I) Pvt. Ltd., Bldg. No. 14, Gala No. 1 to 4, 1 st Fl, Arihant Comm. Complex,
ORDER. Table. Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1. Teneligliptin Hydrobromide + Metformin HCL (SR) Tablet
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of s National Pricing Authority ORDER New
CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 MARKET ANALYSES AND FORECASTS... 2 INTENDED AUDIENCE... 2 INFORMATION SOURCES... 2 ANALYST
Recommendation:- The 19 th SEC - (Oncology & Hematology) deliberated the proposals on and recommended the following:-
Recommendation:- The 19 th SEC - (Oncology & Hematology) deliberated the proposals on 05.11.2014 and recommended the following:- Agend a No. File No. 1. File No.: 12-75/13-DC Afatinib film coated tablet
ORDER. Table. Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1. Rosuvastatin + Clopidogrel Capsule (Crevast CV 20)
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceutical
TRADE MARKS REGISTRY AHMEDABAD
TRADE MARKS REGISTRY AHMEDABAD OPPOSITION HEARING LIST FOR THE MONTH OF JUNE-2016 DATE OF HEARING 13.06.2016 1. 934855/05 Opp. AMD-245342 M/s. Ajanta Pharma Limited, Mumbai / Mr. Manoj G. Menda, Mumbai
Subject: Consolidated list of all cases of price fixation of new drugs received from various companies under para 5 of DPCO 2013
Subject: Consolidated list of all cases of price fixation of new drugs received from various companies under para 5 of DPCO 2013 Sl. No. F.No. Name of the Company/ Formulation Date of receipt of application
Recommendations: Agend a no. Recommendations. Institute. New Drugs Division /12-DC ArbekacinSulphate Injection 200mg/4ml
: I approve the minutes of 32 nd SEC (Antimicrobial, Antiviral, Antiparasitic and Antifungal) held on 11.04.2017 at CDSCO HQ New Delhi and recommended the following: Agend New Drugs Division 1 12-34/12-DC
GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS
GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS HLC029D January 2013 Paul Evers Project Analyst ISBN: 0-89336-238-7 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301
Name of firm/applicant. Torrent Pharmaceuticals. Glenmark Pharmaceuticals. M/s. Torrent Pharmaceutical. Torrent Pharmaceuticals
Recommendation:- The 14 Th SEC (Cardiovascular & Renal) deliberated the proposals on 21.08.2014 and recommended the following:- Agenda no. File no Name of firm/applicant Recommendations 1. 04-228/06-D(pt
New Drugs Division. Frequently Asked Questions (FAQs) on Approval of new Phytopharmaceutical Drugs
Central Drugs Standard Control Organization Directorate General of Health Services Ministry of Health and Family Welfare Government of India New Drugs Division Frequently Asked Questions (FAQs) on Approval
Segment Coverage By Type By Age Group. Global Coverage Regional Coverage Country Coverage
Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (35 years): Forecast to 2022 By Type - Pap Test, HPV Test,
DR. P. V. APPAJI M.Pharm, Ph.D EXECUTIVE DIRECTOR
Date: 7 th July 2006 Dehradun PRESENTATION BY DR. P. V. APPAJI M.Pharm, Ph.D EXECUTIVE DIRECTOR PHARMACEUTICALS EXPORT PROMOTION COUNCIL PHARMACEUTICALS EXPORT PROMOTION COUNCIL SET UP BY MINISTRY OF COMMERCE
Status of Registration Certificate (Form 41) of Human Vaccines issued from 01/03/2015 to 29/05/2015. Human vaccines
Status of Registration Certificate (Form 41) of Human Vaccines issued from 01/03/2015 to 29/05/2015 S. No. Firm Name of Formulation Registration Certificate No. & Validity 1. M/s. Nirlac Chemicals,14 th
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
AGENDA PAPERS FOR THE EIGHTEENTH MEETING SUB-COMMITTEE ON LARGE ANIMALS (SCLA)
AGENDA PAPERS FOR THE EIGHTEENTH MEETING OF SUB-COMMITTEE ON LARGE ANIMALS (SCLA) DATE : 18.04.2005 TIME : 3 : 00 P.M. VENUE : 8 TH FLOOR, JEEVAN PRAKASH BUILDING, 25, KASTURBA GANDHI MARG, NEW DELHI.
Table 1 Details of products supplied and the correlation coefficient of each of these products against its reference.
Table 1 Details of products supplied and the correlation coefficient of each of these products against its reference. Product Number API Test product Dose/ mg Manufacturer Country of manufacture Country
M/s. Hetero Labs Ltd.
:- The 1 st SEC (Gastroenterology&Hepatology) meeting deliberated the proposals on 06.01.2017 and recommended the following:- Agenda New Drugs Division Proposal 1 12-54/16-DC Sofosbuvir and Velpatasvir
Organ Transplantation Market Research Report- Global Forecast Till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/915 Organ Transplantation Market Research Report- Global Forecast Till 2023 Report / Search Code: MRFR/HC/0410-HCRR
TRADE MARKS REGISTRY AHMEDABAD
TRADE MARKS REGISTRY AHMEDABAD OPPOSITION HEARING LIST FOR THE MONTH OF SPTEMBER-2013 DATE OF HEARING 10.09.2013 R. T. M. 1. 842945/16 Rect. AMD-249059 Mr. Pankajbhai Sitaram Nayak, Hearing on Section
Regulatory Reforms-Future of Plasma Protein Therapy in India
Regulatory Reforms-Future of Plasma Protein Therapy in India Ranjeet S. Ajmani PlasmaGen BioSciences Pvt. Ltd. Bangalore, India PPB-2013 Price Tag of Contrast q Uniqueness q Co-existence : Rich & Poor
Ameya works predominantly in the architectural design, interiors and project management segments in healthcare industry
Introduction Ameya design is premier health care consultancy firm with experience with design and execution of largest number of private sector health care facility in India. Key Information Ameya works
Vascular Endothelial Growth Factor Inhibitor Market
May 2017 Report Id : REP-GB-3292 Status : Ongoing Category : Healthcare, Pharmaceuticals & Medical Devices 2015 Future Market Insights, All Rights Reserved About Future Market Insights Future Market Insights
Alpha-fetoprotein (AFP) Testing Market: By Cancer Type (Liver Cancer, Testes Cancer, Ovarian Cancer, Biliary Tract Cancer, Stomach Cancer, Pancreatic
Alpha-fetoprotein (AFP) Testing Market: By Cancer Type (Liver Cancer, Testes Cancer, Ovarian Cancer, Biliary Tract Cancer, Stomach Cancer, Pancreatic Cancer, Others (Cirrhosis, and Hepatitis)) & Geography-Forecast
Name of firm/applicant
Recommendation:- The 18 th Subject Expert Committee (Oncology & Hematology) deliberated the proposals on 04.07.2014 and recommended the following:- Agenda no. Drug name Name of firm/applicant Recommendations
SAMPLE. Asia-Pacific Drug Delivery Devices Market Outlook to Metered Dose Inhaler Devices, Infusion Systems, Central Venous
Asia-Pacific Drug Delivery Devices Market Outlook to 2018 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Others Reference Code: GDME0220RDB Publication Date: January 2013
Exhibitor Prospectus
+ National Meeting and Expo 2018 Exhibitor Prospectus The 2018 Innovatix + Essensa National Meeting & Expo is the only event that provides access to Innovatix and Essensa s most engaged and active members,
Dataset : PharmaTrac MAT MAY PharmaTrac Overview MAY 18
PharmaTrac Overview MAY 18 8434 8956 9655 10422 8112 8917 9549 8258 8921 9406 8668 9630 9381 8662 8373 8999 9013 9796 10413 8742 9315 10050 8458 9180 8601 9092 9767 8364 9145 10583 10173 10387 10217 10476
Solvay in India January, 2014
Solvay in India January, 2014 SOLVAY in India, Innovation and Operational excellence Jodhpur Hichem (JV) Ahmedabad Hichem (JV) Bhiwani Hichem (JV) Delhi Hichem (JV) Solvay R&D center Vadodara Panoli Solvay
III) Firms which attended the pre bid conference are as follows: M/s Becton Dickinson India Pvt. Ltd., Gurgaon
Minutes of Pre-bid meeting held on 24/06/2014 at 14:00 hr at RITES office for Supply of CD4 Enumeration Machines against: IFB RITES/MSM/NACP/05/2014 1. The following were present:- I) From RITES S/Shri
What s New
What s New 23.12.2016 NPPA has fixed/revised ceiling prices of 55 scheduled formulations of Schedule-I under Drugs ( Control) Amendment Order,2016 and Retail of 29 formulations under DPCO, 2013 in related
Merriman Investment Summit 2009
Merriman Investment Summit 2009 10 November 2009 Robert Klupacs, CEO & Managing Director Circadian Technologies (ASX.CIR) Disclaimer Investment in Circadian Technologies Limited ( Circadian ) is subject
Information for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs LIPITOR (atorvastatin calcium) tablets This list does not imply that the products on this chart are interchangeable or have the same efficacy or
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Fri, 19 Apr 2019 13:49:20 GMT) CTRI Number CTRI/2009/091/000126 [Registered on: 15/04/2009] - Last Modified On 03/09/2014 Post Graduate Thesis Type of Trial
REF/2016/08/ CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 26 v 2017 06:12:26 GMT) CTRI Number Last Modified On 08/08/2017 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study Scientific
Country Coverage. Company Coverage
Global Heart Valve Devices Market: Analysis By Procedure (Replacement & Repair), Replacement Procedure By Technique (Mechanical, Bioprosthetic & TAVR), Repair Procedure By Technique (Surgical, Balloon
Oncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
Study of Physicochemical Compatibility of Inhalation Grade Active Ingredients with Propellant HFA 134a by FTIR
Research Article Vinod P. Musale* 1, Dr. SMT. Swati C. Jagdale 2, Dr. Pranav Shah 3 1 Medisol Lifescience Private Limited, Department of Quality Assurance, Gunjan, Vapi (Gujarat), India. 2 MAEER s Maharashtra
Global Aspergillosis Drugs Market Professional Survey Report 2016
Report Information More information from: https://www.wiseguyreports.com/reports/526011 Global Aspergillosis Drugs Market Professional Survey Report 2016 Report / Search Code: WGR526011 Publish Date: 24
14 th SEC- Gastroenterology& Hepatology held on at CDSCO (HQ), FDA Bhawan, Kotla road, NewDelhi
14 th SEC- Gastroenterology& Hepatology held on 27-08-2015 at CDSCO (HQ), FDA Bhawan, Kotla road, NewDelhi 110 002 Recommendation:- The 14 th SEC ( Gastroenterology& Hepatology) meeting deliberated the
Companies Database, Mobile Database, Id Database, Credit
m All India Database We Provides Database Companies Database, Mobile Database, Email Id Database, Credit Card Holder Database, Corporate database, CEO s Database, Corporate Employee Database, Car s Owner
ORDER. Table. Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1. Rosuvastatin Clopidogrel Tablet
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceutical
Patel Krunal M et al. IRJP 2 (2)
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN 223 87 Available online http://www.irjponline.com Research Article DESIGN DEVELOPMENT AND EVALUATION OF MODIFIED RELEASE TABLET OF MONTELUKAST SODIUM BY
Law Relating to. Drugs and Cosmetics. containing. Drugs and Cosmetics Act, 1940 Drugs and Cosmetics Rules, 1945
Law Relating to Drugs and Cosmetics containing Drugs and Cosmetics Act, 1940 Drugs and Cosmetics Rules, 1945 along with Drugs (Prices Control) Order, 2013 National Pharmaceuticals Pricing Policy, 2012
Approved L1 rates and tenderers for 162 Speciality drugs for the year
Approved L1 rates and tenderers for 162 Speciality drugs for the year 2011-2012 Sl. Name of the 1 G3 2 G6 3 G8 Aceclofenac Tab. - Acyclovir Inj., USP - Adefovir Dipivoxil Tab. - 10mg 10 X 10 4899800 Vial
CURRICULUM VITAE Intern in Medicine, Beth Israel Hospital, Harvard Medical School, Boston, MA
Bruce D. Kohrman, M.D. 12305 SW 69 th Place Miami, Florida 33156 Telephone: (305) 903-8678 Fax: (305) 661-1672 CURRICULUM VITAE EDUCATION 1977 - B.S. Stanford University, Stanford, CA 1982 - M.D. Case
REF/2012/08/ CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Fri, 11 May 2018 23:49:14 GMT) CTRI Number Last Modified On 03/05/2013 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
Partial Table of Contents (Contact Client Services to receive complete Table of Contents) IV. Design Criteria for Decentralized Testing Products
Market ation Analysis of the UK Cancer Diagnostics Industry: Oncogenes, Bichemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, and Commercial Labs Partial Table of
Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles
Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles and Others}, Polyenes {Amphotericin B, Candicidin, Hamycin,
Case 3:15-cv PGS-TJB Document 1 Filed 08/04/15 Page 1 of 111 PageID: 1 ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )
Case 3:15-cv-05982-PGS-TJB Document 1 Filed 08/04/15 Page 1 of 111 PageID: 1 Liza M. Walsh Christine I. Gannon CONNELL FOLEY LLP One Newark Center 1085 Raymond Boulevard, 19th Floor Newark, New Jersey
INTRAVENOUS (IV) THERAPY AND VEIN ACCESS: GLOBAL MARKETS
INTRAVENOUS (IV) THERAPY AND VEIN ACCESS: GLOBAL MARKETS HLC046C November 2014 Mary C. Patton Project Analyst ISBN: 1-56965-982-6 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 07 Oct 2018 22:54:26 GMT) CTRI Number Last Modified On 11/05/2018 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Fri, 08 Mar 2019 05:39:17 GMT) CTRI Number Last Modified On 21/11/2018 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
Sample Pages. Needlestick Safety Injection Devices Market, Copyright 2012 Banyan Wharf Consultants Ltd. Page 1
Sample Pages Needlestick Safety Injection Devices Market, 2014-2024 Copyright 2012 Banyan Wharf Consultants Ltd. Page 1 This page is intentionally left blank Copyright 2014 Roots Analysis Private Ltd.
Status of Import License (Form 10) of Recombinant Products, Human and Veterinary Vaccines issued from 30/04/2016 to 20/12/2016
Status of Import License (Form 10) of Recombinant Products, Human and Veterinary Vaccines issued from 30/04/2016 to 20/12/2016 RECOMBINANT PRODUCTS S. No. Firm Name of Formulation Import License No. &
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sat, 24 Nov 2018 11:16:02 GMT) CTRI Number CTRI/2009/091/000668 [Registered on: 11/01/2010] - Last Modified On Post Graduate Thesis Type of Trial Type of
A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database
A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database Contract Research Organization / Terzetto Pharma Metrics NIVETHA CHELLAPATHY
MEETING OF DRUGS TECHNICAL ADVISORY BOARD HELD ON 1 ST APRIL, 2014 IN THE CHAMBER OF DGHS, NIRMAN BHAWAN, NEW DELHI
MINUTES OF THE 67 TH MEETING OF DRUGS TECHNICAL ADVISORY BOARD HELD ON 1 ST APRIL, 2014 IN THE CHAMBER OF DGHS, NIRMAN BHAWAN, NEW DELHI PRESENT 1. Dr. Jagdish Prasad, Chairman Director General of Health
Partial Table of Contents (Contact Client Services to receive complete Table of Contents) IV. Design Criteria for Decentralized Testing Products
Market Segmentation Analysis of the German Cancer Diagnostics Industry: Oncogenes, Bichemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs and Physician
Excipient Regulations Perspective & Creation of IPEC India (Current Regulations & Emerging challenges for excipient regulations in India)
INTERNATIONAL PHARMACEUTICAL EXCIPIENTS COUNCIL OF INDIA (IPEC INDIA) Excipient Regulations Perspective & Creation of IPEC India (Current Regulations & Emerging challenges for excipient regulations in
Global Coverage. Regional Coverage. Company Coverage. Country Coverage. Global Coverage Regional Coverage Country Coverage
Global Influenza Drugs and Vaccines Market By Drugs (Zanamivir, Oseltamivir Phosphate, Peramivir), By Vaccine (Trivalent, Quadrivalent): Analysis By Region, By Country: Opportunities and Forecast (2016-2021)
TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
EAPCI: Biodegradable Scaffolds-Writers 2016
Baumbach Andreas Byrne Robert - Medicines Company : Drugs (2015) - Abbott Vascular : Stents (2015) - Abbott Vascular : Stent (2015) - Boston Scientific : Medical devices (2015) - Biotronik : Medical devices
Information for Vermont Prescribers of Prescription Drugs Long Form Fetzima (levomilnacipran) Extended Release Capsules
Information for Vermont Prescribers of Prescription Drugs Long Form Fetzima (levomilnacipran) Extended Release Capsules The prices listed below are Average Wholesale Prices ( AWP ) as established and made
INDICATIVE SEAT MATRIX - NBE FET CENTRALIZED COUNSELING 2016 ADMISSION SESSION ROUND-2
G B Pant Hospital J L Nehru Marg, Delhi Cardiac Anaesthesia 1 Delhi-110002 Indraprastha s Delhi Cardiac Anaesthesia 1 Medanta- The Medicity Sector-38, Gurgaon, Haryana Cardiac Anaesthesia 5 Haryana-122001
(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
FROST & SULLIVAN. Publications Division - Terms and Conditions of Business
FROST & SULLIVAN Publications Division - Terms and Conditions of Business 1. Frost & Sullivan and FICCI takes no responsibility for any incorrect information supplied by manufacturers or users. Quantitative
Blood Glucose Test Strip Market Research Report- Global Forecast till 2020
Report Information More information from: https://www.marketresearchfuture.com/reports/976 Blood Glucose Test Strip Market Research Report- Global Forecast till 2020 Report / Search Code: MRFR/MED/0470-CRR
100 Abbott Park Road Abbott Park, IL Trade Name: ARCHITECT HIV Ag/Ab Combo Assay Approved Date: 18-JUN-2010
Currently Approved CBER Device Premarket Applications (PMAs) As of Nov 10, 2014 Sorted by Applicant Name BP090080-0 BP060002-0 BP120037-0 BP090022-0 BP090032-0 BP040046-0 BP100064-0 BP140120-0 Abbott Laboratories